Recombinant Human Anti-CD19 x Human Anti-CD28 Bispecific Antibody (scFv-Fc) (BSCFV-H217)

Recombinant Anti-CD19 x Anti-CD28 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD19 specificity or anti-CD28 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD28

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Human Anti-CD28 Bispecific Antibody (scFv-Fc) (BSCFV-H217). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD19 x Human Anti-CD28 Bispecific Antibody (scFv-Fc) (CAT#: BSCFV-H217)

Specifications

Targets

Customer Reviews and Q&As